http://hdl.handle.net/20.500.12566/1089 2026-04-08T08:59:24Z 2026-04-08T08:59:24Z Sarıer, Mehmet Sepin, Nevgün Emek, Mestan Yenidünya Konuk, Elçin Kaplan, Tuğrul Aykan Yüksel, Burcu Barut, Zerrin Sakallı Çakçak, Devrim Hoşcan, Mustafa Burak http://hdl.handle.net/20.500.12566/1989 2024-03-25T10:56:32Z 2023-01-01T00:00:00Z

Evaluation of the optimal sampling approach for HPV genotyping in circumcised heterosexual men with genital warts Sarıer, Mehmet; Sepin, Nevgün; Emek, Mestan; Yenidünya Konuk, Elçin; Kaplan, Tuğrul; Aykan Yüksel, Burcu; Barut, Zerrin; Sakallı Çakçak, Devrim; Hoşcan, Mustafa Burak Background: Human papillomavirus (HPV) causes a serious socioeconomic burden globally. However, there is currently no consensus on the optimal sampling method for HPVDNA genotyping in circumcised heterosexual men. This study aimed to determine the diagnostic efficacy of 6 different anatomic sampling sites in HPV DNA polymerase chain reaction (PCR) testing of circumcised heterosexual men with genital warts. Methods: The study included circumcised heterosexual men who presented to our clinic with complaints of genital warts. Swab samples were obtained from the penile shaft (PS), scrotum, coronal sulcus (CS), and external urethral meatus (EUM). First-void urine (FVU) and genital wart biopsy (GWB) were also tested for HPV DNA by PCR. Results: A total of 32 patients (mean age: 36.9 ± 6.9 years) were included. None of the six samples studied was sufficient on its own to reveal all HPV types detected in a patient. When the samples were analyzed individually, GWB detected an average of 49.5% of total HPV types in a patient. This rate was 50.5% for PS, 40.4% for CS, 31.6% for scrotum, 26.3% for EUM, and 15.8% for FVU samples. The detection rate increased to 75.8% with combined testing of GWB and PS samples, 83.2% with GWB/PS/CS, 90.5% with GWB/PS/CS/scrotum, and 98.9% with GWB/PS/CS/scrotum/EUM samples. Conclusion: No single anatomic region or sample type can detect all HPV types present in circumcised heterosexual men by PCR assay. The detection rate approaches 99% when wart biopsy is combined with swab sampling of the penile shaft, coronal sulcus, scrotum, and external urethral meatus.

2023-01-01T00:00:00Z Barut, Zerrin Cabbar, Ayça Türer Güleç Yılmaz, Seda Akdeniz, Fatma Tuba Simsek, Mustafa Aytek Capar, Betül Degertekin, Muzaffer Dalan, Altay Burak Yerebakan, Halit İsbir, Turgay http://hdl.handle.net/20.500.12566/1199 2023-12-07T07:29:05Z 2021-01-01T00:00:00Z

Investigation of circulating miRNA-133, miRNA-26, and miRNA-378 as candidate biomarkers for left ventricular hypertrophy Barut, Zerrin; Cabbar, Ayça Türer; Güleç Yılmaz, Seda; Akdeniz, Fatma Tuba; Simsek, Mustafa Aytek; Capar, Betül; Degertekin, Muzaffer; Dalan, Altay Burak; Yerebakan, Halit; İsbir, Turgay Background/aim: Left ventricular hypertrophy (LVH) involves increased muscular mass of the left ventricle due to increased cardiomyocyte size and is caused by cardiomyopathies. Several microRNAs (miRNAs) have been implicated in processes that contribute to heart disease. This study aimed to examine miRNA-133, miRNA-26 and miRNA-378 as candidate biomarkers to define prognosis in patients with LVH. Patients and methods: The study group consisted of 70 patients who were diagnosed with LVH and 16 unaffected individuals who served as the control group. Real-time polymerase chain reaction (RT-PCR) was used to analyze serum miRNA-133, miRNA-26, and miRNA-378 expression levels in LVH patients and the control group. Receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic capability of miRNA-378. Results: When crossing threshold (CT) values were compared between patient and control samples, we found that there were no statistically significant differences in miRNA-133 and miRNA-26 CT values, while the miRNA-378 expression was significantly increased in LVH patients. ROC analysis demonstrated that the expression levels of miRNA-378 (AUC=0.484, p=0.0013) were significantly different between groups. Conclusion: We observed a statistically significant relationship between miRNA-378 expression levels and LVH, suggesting that circulating miRNA-378 may be used as a novel biomarker to distinguish patients who have LVH from those who do not.

2021-01-01T00:00:00Z Güleç Yılmaz, Seda Yenilcek, Faruk Yıldırım, Asıf Akdeniz, Fatma Tuba Dalan, Altay Burak Barut, Zerrin İsbir, Turgay http://hdl.handle.net/20.500.12566/1198 2023-12-07T07:29:22Z 2021-01-01T00:00:00Z

The role of Kallikrein10 (KLK10) polymorphism in prostate cancer susceptibility Güleç Yılmaz, Seda; Yenilcek, Faruk; Yıldırım, Asıf; Akdeniz, Fatma Tuba; Dalan, Altay Burak; Barut, Zerrin; İsbir, Turgay Purpose: The present study aims to investigate the potential role of Kallikrein 10 (KLK10) genotype and allele frequencies in predisposition to prostate cancer. Materials and methods: KLK10 (rs7259451) gene polymorphisms were determined by real-time polymerase chain reaction analysis in patients with prostate cancer (n=69) and controls (n=76). Results: KLK10 gene frequencies were significantly different in the case and control groups (P = .028). GG carriers were significantly higher in the control group (P = .034), whereas TT carriers were higher in the prostate cancer group (P = .033). Furthermore, The patients with GG genotype had the lowest PSA levels while TT carriers had the highest (P = .005). Conclusion: According to the results, we suggested that carrying variant T allele and also carrying homozygote TT genotype could be a potential risk, while ancestral homozygote GG genotype and G allele are risk reducing factors for prostate cancer.

2021-01-01T00:00:00Z Abaoğlu, İpek Yağmur Güleç Yılmaz, Seda Akdeniz, Fatma Tuba Attar, Rukset Barut, Zerrin Dalan, Altay Burak İsbir, Turgay http://hdl.handle.net/20.500.12566/1197 2023-12-07T07:29:38Z 2021-01-01T00:00:00Z

Investigation of catechol-o-methyltransferase (comt) gene Val158Met polymorphism in ovarian cancer Abaoğlu, İpek Yağmur; Güleç Yılmaz, Seda; Akdeniz, Fatma Tuba; Attar, Rukset; Barut, Zerrin; Dalan, Altay Burak; İsbir, Turgay Objective: Catechol-o-methyltransferase (comt), the product of the COMT gene, detoxifies the carcinogenic catechol estrogens. The aim of the present study was to examine the relationship between comt Val158Met polymorphism and the risk of ovarian cancer. Material and methods: The study groups consist of 94 individuals as a patients group with ovarian cancer (n=47) and control group (n=47). The allele and genotype frequencies were determined according to Hardy-Weinberg equilibrium (HWE). The allele and genotype frequencies. determined according to HWE. Genetic analysis were performed by real-time-polymerase chain reaction instrument, and the statistical analysis were performed by SPSS program. Results: Although no significant relationship was obtained among groups (p=0.413) regarding comt gene Val158Met polymorphism, the genotype frequencies for comt Val158Met (rs4860) polymorphism in groups was homozygote wild type GG genotype 25.5%, heterozygote GA genotype 46.8%, homozygote mutant AA genotype 27.7%. Conclusion: This study is the first to investigate the relationship between ovarian cancer and the Val158Met polymorphism in the comt gene in a Turkish population. No statistically significant relationship was identified among genotypes belonging to the patient and control groups although sample sizes were relatively small and the analysis should be repeated in a larger cohort.

2021-01-01T00:00:00Z